📊 BNGO Key Takeaways
Investment Thesis
Bionano Genomics is a pre-revenue/early-stage company with severe profitability issues, burning significant cash while generating minimal revenue that is declining year-over-year. The company faces an existential challenge with negative operating margins of -120.7% and operating cash burn of -$12.2M annually, while cash reserves of only $3.1M provide limited runway.
BNGO Strengths
- Zero long-term debt provides financial flexibility without debt service obligations
- Adequate liquidity with 2.12x current ratio and $3.1M cash suggests short-term solvency
- Operating in laboratory analytical instruments sector with potential market opportunities if technology gains adoption
BNGO Risks
- Severe cash burn of -$12.2M annually with only $3.1M in cash reserves implies approximately 3 months of runway at current burn rates
- Revenue declining 14.8% YoY while operating losses widen, indicating deteriorating business fundamentals and lack of market traction
- Negative net margin of -89.8% and ROE of -37.1% demonstrate the company is destroying shareholder value and not achieving profitability milestones
- High insider trading activity (10 Form 4 filings in 90 days) may suggest management uncertainty or position adjustments
Key Metrics to Watch
- Cash runway and path to cash flow breakeven given current burn rate
- Revenue trajectory and ability to reverse YoY decline
- Operating expense reduction and progress toward operating profitability
BNGO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.12x current ratio provides a solid financial cushion.
BNGO Profitability Ratios
BNGO vs Default Sector
How Bionano Genomics, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BNGO Balance Sheet & Liquidity
BNGO 5-Year Financial Trend
5-Year Trend Summary: Bionano Genomics, Inc.'s revenue has grown significantly by 257% over the 5-year period, indicating strong business expansion. The most recent EPS of $-408.60 indicates the company is currently unprofitable.
BNGO Growth Metrics (YoY)
BNGO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.1M | -$3.1M | $-1.59 |
| Q2 2025 | $6.7M | -$3.1M | $-1.99 |
| Q1 2025 | $6.5M | -$3.1M | $-1.15 |
| Q3 2024 | $6.1M | -$16.2M | $-0.52 |
| Q2 2024 | $7.8M | -$16.2M | $-0.24 |
| Q1 2024 | $7.4M | -$31.4M | $-0.60 |
| Q3 2023 | $7.2M | -$30.0M | $-1.10 |
| Q2 2023 | $6.7M | -$30.0M | $-1.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BNGO Capital Allocation
BNGO SEC Filings
Access official SEC EDGAR filings for Bionano Genomics, Inc. (CIK: 0001411690)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BNGO
What is the AI rating for BNGO?
Bionano Genomics, Inc. (BNGO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BNGO's key strengths?
Zero long-term debt provides financial flexibility without debt service obligations. Adequate liquidity with 2.12x current ratio and $3.1M cash suggests short-term solvency.
What are the risks of investing in BNGO?
Severe cash burn of -$12.2M annually with only $3.1M in cash reserves implies approximately 3 months of runway at current burn rates. Revenue declining 14.8% YoY while operating losses widen, indicating deteriorating business fundamentals and lack of market traction.
What is BNGO's revenue and growth?
Bionano Genomics, Inc. reported revenue of $20.6M.
Does BNGO pay dividends?
Bionano Genomics, Inc. does not currently pay dividends.
Where can I find BNGO SEC filings?
Official SEC filings for Bionano Genomics, Inc. (CIK: 0001411690) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BNGO's EPS?
Bionano Genomics, Inc. has a diluted EPS of $-4.82.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.